Novo Nordisk's Double Bill: ASCO Hints at Broader GLP-1 Potential Ahead of ADA Pipeline Readout

A pair of scientific conferences are converging to reshape the narrative around Novo Nordisk, just as the Danish drugmaker’s stock attempts to claw back from a year-long rout. Data presented at the American Society of Clinical Oncology (ASCO) meeting has thrown a spotlight on the cancer-fighting potential of GLP-1 therapies, while next week’s American Diabetes Association (ADA) gathering in New Orleans will test the commercial heft of the company’s next-generation pipeline. For a share trading 44% below its 52-week high, the stakes are high.

The ASCO analysis, drawn from medical records of more than 12,000 cancer patients treated with diabetes drugs, found that those on GLP-1 medications faced a 38% to 50% lower risk of metastasis to stage IV in four of seven obesity-linked cancers — lung, breast, colon and liver — compared with a group receiving older gliptin therapies. Cancer Research UK was quick to stress the observational nature of the data, cautioning that no causal link has been established and that controlled clinical trials are needed before GLP-1s could enter oncology protocols. Still, the findings feed a growing conviction among investors that the biological reach of this drug class extends far beyond blood sugar control and weight loss.

That long-term thesis will be tested in the near term by the ADA’s 86th Scientific Sessions, running from 5 to 8 June in New Orleans. Novo Nordisk plans to unveil 40 abstracts, with the spotlight trained on phase 3 data from the REIMAGINE 1–3 studies of CagriSema — the company’s most important pipeline candidate, combining an amylin receptor agonist with a GLP-1 receptor agonist. Alongside, phase 2 results for Zenagamtide, another weekly injectable pairing GLP-1 and amylin mechanisms, will help investors gauge how broad the next product generation can truly be. A dedicated R&D investor webcast is scheduled for 7 June at 16:30 CDT, where management is expected to contextualise the findings and lay out pipeline priorities.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The clinical calendar arrives alongside encouraging commercial signals. The oral version of semaglutide — the Wegovy pill — generated roughly 18,410 prescriptions in its first week on the US market, dwarfing the 3,707 scripts clocked by Eli Lilly’s oral competitor Foundayo over a comparable launch period. Crucially, about 80% of Wegovy pill users had no prior GLP-1 exposure, suggesting the tablet is expanding the addressable patient pool rather than merely cannibalising existing injections. European momentum is also building: on 22 May, the CHMP recommended approval of both Wegovy HD (a higher 7.2 mg dose) and the oral Wegovy formulation.

Despite these tailwinds, Novo Nordisk’s financial outlook remains tempered. The company reiterated its 2026 guidance for a currency-adjusted revenue decline of 4% to 12% — a slight improvement on the previous range, driven by stronger GLP-1 expectations, but still weighed down by lower realised prices, the US Most Favoured Nation agreement, loss of semaglutide exclusivity in certain markets, intensifying competition, and reduced Medicaid reimbursement for obesity drugs. The stock closed at €39.05 in Frankfurt on Friday, virtually flat on the day but up roughly 13% over the past month. Over 12 months, however, the decline stands at 35.7%, while the split-adjusted record high of $81.44 from the prior year remains a distant memory.

Trading at a trailing price-to-earnings ratio of 10.69 — below its five-year median — the stock offers a valuation that reflects both the pipeline promise and the commercial headwinds. The immediate catalyst will be whether the ADA data can reinforce the narrative of a durable competitive moat, or whether the market treats them as incremental noise. The cancer study has already added a new dimension to the GLP-1 story, but the proof of clinical and commercial execution now rests on the presentations in New Orleans.

Ad

Novo Nordisk Stock: New Analysis - 31 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69454265 |